Tenaya Therapeutics (TNYA) Cash from Financing Activities (2020 - 2026)

Tenaya Therapeutics' Cash from Financing Activities history runs 7 years deep, the most recent figure standing at -$415000.0 for Q1 2026.

• On a quarterly basis, Cash from Financing Activities fell 100.83% year-over-year to -$415000.0 in Q1 2026; TTM through Mar 2026 was $57.7 million, a 12.67% increase from a year earlier, with the FY2025 full-year figure at $108.4 million, up 127.03% from the prior year.
• Cash from Financing Activities retreated to -$415000.0 in Q1 2026 per TNYA's latest filing, from $58.2 million in the prior quarter.
• Across five years, Cash from Financing Activities topped out at $77.5 million in Q4 2022 and bottomed at -$501000.0 in Q1 2023.
• The 5-year median for Cash from Financing Activities is $374000.0 (2023), against an average of $14.8 million.
• Across the five-year window, Cash from Financing Activities soared 369080.95% in 2022 and tumbled 3440.0% in 2023, its largest moves.
• Year by year, Cash from Financing Activities stood at $77.5 million in 2022, then tumbled by 99.52% to $371000.0 in 2023, then gained by 1.62% to $377000.0 in 2024, then jumped by 15348.81% to $58.2 million in 2025, then sank by 100.71% to -$415000.0 in 2026.
• Per Business Quant, the three latest TNYA Cash from Financing Activities figures stand at -$415000.0 (Q1 2026), $58.2 million (Q4 2025), and $380000.0 (Q3 2025).